Baiyi Biopharmaceutical
Therapeutics for episodic and chronic migraine treatment
About Baiyi Biopharmaceutical
Baiyi Biopharmaceutical is a biopharmaceutical company established in 2021 and headquartered in Hangzhou, China. The company focuses on the research and development of drugs for difficult-to-treat neurological conditions, specifically targeting episodic and chronic migraines.
The firm operates in the biopharmaceutical sector, concentrating on creating a pipeline of proprietary assets. Its business model is centered on the in-house development of therapeutics. The company's objective is to address the medical needs of patients suffering from neurological diseases by providing new treatment options.
In April 2024, Baiyi Biopharmaceutical secured an undisclosed amount in an angel funding round. The round was led by Transfar and Tailong Investment, with participation from Qinzhi Capital. This investment supports the company's ongoing research and development activities as it advances its drug candidates through the discovery and preclinical stages.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Drug Development, Neurology, Chronic Disease, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jan 2026 | $14M | $55M | Longpan Investment · SHC Shanghai Biomedical Fund · Hangzhou Capital | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
| Huangpu, China | Operational | — | $2.8M | $11M | |
Convergen PharmaceuticalsTargeted protein degradation therapies for neurodegenerative diseases |
Suzhou Shi, China | Operational | |||
| Somerville, United States | Operational | ||||
CUREVERSESmall-molecule drug discovery for treating brain diseases |
Seoul, South Korea | Operational | |||
CrestecBioCrestecbio Company's headquarters in Miyagi City, Director-in-Chief-Cashima |
Tsukuba, Japan | Operational | |||
EndocuraLocalized vascular-targeted therapies for cancer treatment |
Incheon, South Korea | Operational | |||
Scripta TherapeuticsAI-driven drug discovery modulating transcription factor activity |
Oxford, United Kingdom | Operational | |||
AeroRx TherapeuticsNebulized combination therapies for chronic respiratory diseases |
San Diego, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Baiyi Biopharmaceutical in the Hangzhou ecosystem
The Baiyi Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- LILongpan Investment
SHC Shanghai Biomedical Fund
Hangzhou Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Baiyi Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Baiyi Biopharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







